Galera Therapeutics, Inc. services

Radiation Therapy-Induced Oral Mucositis: Oral mucositis (OM) is a common and debilitating toxicity for patients being treated with radiation therapy for head and neck cancers (HNC). OM consists of redness (erythema), swelling, sores (ulcers) and breakdown of the oral mucosa, or lining of the oral cavity. OM causes substantial pain and can interfere with the patient’s ability to eat and/or drink.1 Approximately 60-70% of patients with HNC receiving cisplatin and radiation therapy develop Severe Oral Mucositis (SOM) (Grade 3 or Grade 4 OM).

We believe that precisely targeting oxygen metabolic pathways has the potential to offer unique and powerful strategies for treating cancer and addressing treatment-related side effects such as oral mucositis.

Harnessing the Anticancer Power of Hydrogen Peroxide: As cancer cells are more susceptible than normal cells to increased levels of hydrogen peroxide, we believe the conversion of radiation-generated superoxide to hydrogen peroxide by our selective dismutase mimetics can improve outcomes for patients who receive radiation therapy.

The cornerstone of our work is the recognition that oxygen metabolic pathways play important roles in human biology and disease.